Icon

SYMLIN (nda021332)- (EQ 3MG BASE/5ML (EQ 600MCG BASE/ML),EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML),EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML))

PRAMLINTIDE ACETATE ASTRAZENECA AB
EQ 3MG BASE/5ML (EQ 600MCG BASE/ML),EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML),EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)
No No
2019-Mar-16 Expired
None None
None No
SYMLIN is an amylin analog indicated for patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy.
0 0 0
Total Other Developers 2
Drugs with Suitability No
EQ 3MG BASE/5ML (EQ 600MCG BASE/ML) ** ** - - -
EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML) ** ** - - -
EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.